Grand Pharmaceutical GroupCGPHF 87 ROE % is 0.84% as of Dec. 2025, which is 95% below its 10-year median of 15.37. GuruFocus rates CGPHF with a GF Score™ of 87/100. The stock has 6 warning signs investors should review. Among 936 Drug Manufacturers companies, Grand Pharmaceutical Group ranks better than 54.27% on this metric.
The historical rank and industry rank for Grand Pharmaceutical Group's ROE % or its related term are showing as below:
CGPHF'
s ROE % Range Over the Past 10 Years
Min: 7.41 Med: 15.37 Max: 23.41
Current: 7.35
During the past 13 years, Grand Pharmaceutical Group's highest ROE % was 23.41%. The lowest was 7.41%. And the median was 15.37%.
CGPHF's ROE % is ranked better than 54.27% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs CGPHF: 7.35
Grand Pharmaceutical Group (OTCPK:CGPHF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's ROE % distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Grand Pharmaceutical Group (CGPHF) has a ROE % of 0.84% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Grand Pharmaceutical Group and its competitors. This is 95% below median its historical median of 15.37. Over the past decade, Grand Pharmaceutical Group's ROE % has ranged from 7.41 to 23.41. According to the industry distribution chart, Grand Pharmaceutical Group ranks #428 out of 936 companies in the Drug Manufacturers industry, placing it in the top 45.7%.
Is Grand Pharmaceutical Group's ROE % too high?
Grand Pharmaceutical Group's current ROE % of 0.84% is 95% below median its 10-year median of 15.37. Over the past 10 years, this metric has ranged from a low of 7.41 to a high of 23.41. The Drug Manufacturers industry median ROE % is 5.87. Grand Pharmaceutical Group's value of 0.84% is 85.7% below this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #428 out of 936 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grand Pharmaceutical Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #428 out of 936 companies for ROE %. This puts Grand Pharmaceutical Group in the upper half of its industry. The industry median ROE % is 5.87. Grand Pharmaceutical Group's value of 0.84% is 85.7% below this benchmark. Historically, Grand Pharmaceutical Group's own ROE % has ranged from 7.41 to 23.41 over the past decade. While the company's 10-year median is 15.37 vs. the industry median of 5.87, Grand Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current ROE % of 0.84% is 85.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current ROE % is 0.84%, which is 95% below median its own 10-year median of 15.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current ROE % of 0.84%. The current ROE % is 0.84%, which is 95% below median its 10-year median of 15.37 and 85.7% below the Drug Manufacturers industry median of 5.87. Grand Pharmaceutical Group's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current ROE % is 0.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGPHF has been successfully added to your 